Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

cis bio international - cloreto taloso (201tl) - solução injetável - 37 mbq/ml - cloreto taloso (201tl) 37 mbq/ml - thallium (201tl) chloride - radiofármaco - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

curium netherlands b.v. - cloreto taloso (201tl) - solução injetável - 37 mbq/ml - cloreto taloso (201tl) 37 mbq/ml - thallium (201tl) chloride - radiofármaco - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

curium netherlands b.v. - cloreto taloso (201tl) - solução injetável - 37 mbq/ml - cloreto taloso (201tl) 37 mbq/ml - thallium (201tl) chloride - radiofármaco - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

curium netherlands b.v. - cloreto taloso (201tl) - solução injetável - 37 mbq/ml - cloreto taloso (201tl) 37 mbq/ml - thallium (201tl) chloride - radiofármaco - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

curium netherlands b.v. - cloreto taloso (201tl) - solução injetável - 37 mbq/ml - cloreto taloso (201tl) 37 mbq/ml - thallium (201tl) chloride - radiofármaco - duração do tratamento: curta ou média duração

União Europeia - português - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tipo 2 - drogas usadas em diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

União Europeia - português - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - imagem de radionuclídeos - rádiofarmacêutica terapêutica - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.